Phase I/II Trial of Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2014 by Columbia University
Sponsor:
Collaborator:
Incyte Corporation
Information provided by (Responsible Party):
Kevin Kalinsky, Columbia University
ClinicalTrials.gov Identifier:
NCT02066532
First received: February 18, 2014
Last updated: July 22, 2014
Last verified: July 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: December 2017
  Estimated Primary Completion Date: June 2017 (Final data collection date for primary outcome measure)